Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

Cell and gene therapies using haematopoietic stem cells (HSCs) epitomize the
transformative potential of regenerative medicine. Recent clinical successes for gene …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment
option for individuals with B cell malignancies but have yet to achieve success in treating …

Targeted eradication of transformed or otherwise dysregulated cells using monoclonal
antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric …

Ex vivo autologous hematopoietic stem cell (HSC) gene therapy has provided new therapies
for the treatment of hematological disorders. However, these therapies have several …

Chimeric antigen receptor (CAR) T cells hold promise for the treatment of acute myeloid
leukemia (AML), but optimal targets remain to be defined. We demonstrate that CD93 CAR T …

Since the late 1980s, mice have been repopulated with human hematopoietic cells to study
the fundamental biology of human hematopoiesis and immunity, as well as a broad range of …

The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either
the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine …

The encoding of chemical compounds with amplifiable DNA tags facilitates the discovery of
small-molecule ligands for proteins. To investigate the impact of stereo-and regiochemistry …